Pharmacists in New York State are invited to attend a free virtual continuing education series led by a team of multi-disciplinary experts working to end the opioid crisis in New York State. Continuing pharmacy education credits will be available.
The educational series will convene on Sunday, October 3, 2021, from 9 a.m. to 10:30 a.m. and will continue on October 17, October 24, and October 31, 2021, at that time. Participants may choose to attend any number sessions.
Topics will include: reducing overdose deaths through increasing access to naloxone; equity in access; medication for opioid use disorder; COVID-19 services; medication for addiction treatment; pharmacology, misconceptions, and myths; harm reduction; optimizing pharmacy interventions in New York State; and the legal dimensions in responding to the opioid crisis.
The educational series is co-sponsored by the National Institutes of Health HEAL Initiative Planning Committee of Cayuga, Columbia, Putnam, and Suffolk counties and the Albany College of Pharmacy and Health Sciences.
To register for any or all CEs, visit:
https://pharmacyce.acphs.edu/user/login.
Response to the Opioid Crisis: Legal Dimensions & Harm Reduction
Speaker: Karl Williams, RPh, JD, St. John Fisher College, President, Pharmacists Society of the State of New York, Professor, Wegmans School of Pharmacy
UAN# 0045-9999-21-021-L01-P / 0.15 CEUs
Learning Objectives:
- Describe New York State laws surrounding dispensing of controlled substances and opioids
- Review regulatory responses intended to mitigate the opioid epidemic: rules, regulations, and changes
- Review required counseling items and revisioning the role of the pharmacists in pharmacists in dispensing of opiates and opioid use
- Propose an expanded role for pharmacists in combatting the opioid crisis.
Intended Audience: Pharmacists in the State of NY
Live On-line Webinar: Attendees who register for remote viewing will receive a link to attend the program using their computer, tablet or phone, along with instructions to access Zoom Meeting one week prior to the webinar. You will be able to listen to the speakers and view the educational materials and respond to polling questions. In order to qualify as a live activity, questions may be posed to the presenters by means of the on-line chat function.
Continuing Education: Continuing Education credit has been approved for up to 6 live Continuing Education Units (CEUs) or 0.6 Contact Hours of live Continuing Education. Participants must log in using your full name so that proof of participation can be confirmed. Participants must also complete the online learning assessments for the activity attended after the program to receive credit for this activity. You will have 45 days from the day of the program to complete the evaluations and learning assessments to receive ACPE credit. Upon completion and verification, your continuing pharmacy education credits will be sent to CPE Monitor. Statements of credit may be printed from the CPE Monitor website at: www.nabp.net/pharmacists.
ACPE policy states that paper and/or electronic statements of credit are no longer required to be distributed directly to learners as proof of ACPE credit. This official record of credit is located on the learner's e-profile in CPE Monitor. Printed copies of statements will no longer be distributed by Albany College of Pharmacy and Health Sciences.
Registration Fee: There is not a fee to attend this Continuing Education Program. However, registration is required in order for us to send you the program handouts and Zoom Meeting link. The deadlines to register for each session are as follows:
- Friday, October 29: Response to the Opioid Crisis: Legal Dimensions & Harm Reduction
Register by visiting: https://pharmacyce.acphs.edu/user/login.
Statement of Disclosure: In accordance with ACPE Standards, ACPHS requires that speakers and program planners disclose any relationships that they may have with commercial interests whose products or services may be mentioned in their presentations. All speakers and program planners involved in this series have no disclosures or conflicts of interest.